Progenity has appointed Jeffrey Alter, John Bigalke, Samuel Nussbaum, and Lynne Powell to its board of directors.
Alter is president of Arcturus One Consulting. He previously served as CEO of UnitedHealthcare's commercial group. Prior to that, he was senior VP of strategic financial planning for Oxford Health Plans. Before Oxford, he served as VP of finance, underwriting, and operations at Vytra Health Plans.
Bigalke is CEO of Second Half Healthcare Advisors. He is also chairman of VaxCares' advisory board and a member of Advent (formerly Adventist) Health System's advisory board. In addition, he is a senior advisor to Concord Management Services. Bigalke previously served as US national industry leader and senior partner for global healthcare and life sciences at Deloitte. Bigalke also was the firm's national director of public policy.
Nussbaum is a professor of clinical medicine at the Washington University School of Medicine. He is also a strategic consultant for EBG Advisors and a senior advisor to Sandbox Industries and the Ontario Teachers' Pension Plan. He serves on several boards, including those of Motus GI, Coherus Biosciences, and PhyMed. Prior to this, Nussbaum served as executive VP of clinical health policy and chief medical officer at Anthem. Previously, he was executive VP of medical affairs and system integration at BJC Healthcare.
Powell serves as senior VP and chief commercial officer at BioCryst Pharmaceuticals. Prior to this, she was senior VP of North America at CSL Behring. Powell also served as the firm's VP of global commercial development and head of business development and European marketing. Prior to CSL, she held positions at Glaxo Wellcome's commercial strategy and clinical research organizations.